马耿,张丽贤

• 1:衡水市人民医院消化内科

摘要(Abstract)：

目的分析标准四联疗法对幽门螺杆菌阳性慢性萎缩性胃炎(chronic atrophic gastritis,CAG)患者血清生长激素(growth hormone,GH)、胃蛋白酶原Ⅰ(pepsinogenⅠ,PGⅠ)、胃蛋白酶原Ⅱ(pepsinogenⅡ,PGⅡ)、白介素(interleukin,IL)及转化生长因子-β_1(transforming growth factor-β1,TGF-β1)水平及预后的影响,探讨其临床应用价值及作用机制。方法选取本院2014年8月至2017年10月收治的75例幽门螺杆菌阳性CAG患者纳入观察组,均给予标准四联疗法治疗,持续2周;分别于治疗前后检测观察组患者血清GH、PGⅠ、PGⅡ、IL及TGF-β_1水平。选取同期于本院体检的60例健康体检者纳入对照组,检测其入组时上述血清指标水平并与观察组患者进行比较,分析观察组患者治疗效果。结果观察组患者治疗后血清GH、PGⅠ、PGⅡ水平均显著高于治疗前(P_均<0.05),血清IL-10、IL-17、TGF-β_1水平均显著低于治疗前(P_均<0.05);治疗前后观察组患者血清GH、PGⅠ、PGⅡ水平均显著低于对照组(P_均<0.05),血清IL-10、IL-17、TGF-β_1水平均显著高于对照组(P_均<0.05)。观察组患者治疗后~(13)C尿素呼气试验转阴率为93.33%(70/75)。显效36例,有效23例,无效16例,治疗总有效率为78.67%(59/75)。结论标准四联疗法治疗幽门螺杆菌阳性CAG疗效确切,幽门螺杆菌转阴率满意,其作用机制可能与抑制炎性反应、促进胃黏膜损伤修复有关。

关键词(KeyWords)： 四联疗法;幽门螺杆菌;慢性萎缩性胃炎;炎性因子

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 马耿,张丽贤

参考文献(References)：

• [1]Sugano K,Tack J,Kuipers EJ,et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut,2015,64(9):1353-1367.
• [2]Yoshida T,Kato J,Inoue I,et al.Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer[J].Int J Cancer,2014,134(6):1445-1457.
• [3]Gao X,Zhang Y,Brenner H.Associations of Helicobacter pylori infection and chronic atrophic gastritis with accelerated epigenetic ageing in older adults[J].Br J Cancer,2017,117(8):1211-1214.
• [4]施尧.慢性胃炎的萎缩诊断标准和分期分级[J].胃肠病学,2006,11(4):195-197.
• [5]方小鹤.Hp根除对Hp相关慢性胃病患者血清G17及PG的影响及其临床价值[D].长春:吉林大学,2015.
• [6]郭敏,李佃贵.化浊解毒治萎方对Hp阳性慢性萎缩性胃炎患者血清PGⅠ/PGⅡ的影响[J].环球中医药,2016,9(11):1293-1296.
• [7]Chen XZ,Sch?ttker B,Castro FA,et al.Association of helicoba cter pylori infection and chronic atrophic gastritis with risk of colonic,pancreatic and gastric cancer:A ten-year followup of the ESTHER cohort study[J].Oncotarget,2016,7(13):17182-17193.
• [8]Kobayashi S,Ogura M,Suzawa N,et al.18F-FDG uptake in the stomach on screening PET/CT:value for predicting Helicobacter pylori infection and chronic atrophic gastritis[J].BMC Med Imaging,2016,16(1):58.
• [9]Jeong M,Park JM,Han YM,et al.Dietary Intervention of Artemisia and Green Tea Extracts to Rejuvenate Helicobacter pylori-Associated Chronic Atrophic Gastritis and to Prevent Tumorigenesis[J].Helicobacter,2016,21(1):40-59.
• [10]文辉,贺玉梅.应用益气养阴活血方治疗慢性萎缩性胃炎患者的效果观察[J].转化医学电子杂志,2015,2(3):101.
• [11]van der Post RS,van Dieren J,Grelack A,et al.Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria[J].Gastrointest Endosc,2018,87(2):397-404.
• [12]Jeong S,Choi E,Petersen CP,et al.Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinomaassociated chronic atrophic gastritis[J].United European Gastroenterol J,2017,5(1):37-44.
• [13]蔡安健.四联疗法根除幽门螺杆菌67例疗效观察[J].医学信息,2013,9(26):490-493.
• [14]Park YH,Kim N.Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer[J].JCancer Prev,2015,20(1):25-40.
• [15]马阿火.慢性萎缩性胃炎血清生长激素水平的研究[D].杭州:浙江大学,2001.
• [16]Inoue I,Kato J,Tamai H,et al.Helicobacter pylori-related chronic gastritis as a risk factor for colonic neoplasms[J].World J Gastroenterol,2014,20(6):1485-1492.
• [17]Watari J,Chen N,Amenta PS,et al.Helicobacter pylori associated chronic gastritis,clinical syndromes,precancerous lesions,and pathogenesis of gastric cancer development[J].World J Gastroenterol,2014,20(18):5461-5473.
• [18]马健,孟欣颖,王涛,等.慢性活动性胃炎患者血清IL-6、TGF-β1及IL-17的水平与幽门螺杆菌的关系及临床意义[J].中华临床医师杂志(电子版),2012,6(11):2908-2910.